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Interleukin-2 (IL-2) regulates lymphocyte function by
signaling through heterodimerization of the IL-2Rb
and gc receptor subunits. IL-2 is of considerable
therapeutic interest, but harnessing its actions in a
controllable manner remains a challenge. Previ-
ously, we have engineered an IL-2 ‘‘superkine’’ with
enhanced affinity for IL-2Rb. Here, we describe
next-generation IL-2 variants that function as ‘‘re-
ceptor signaling clamps.’’ They retained high affinity
for IL-2Rb, inhibiting binding of endogenous IL-2, but
their interaction with gc was weakened, attenuating
IL-2Rb-gc heterodimerization. These IL-2 analogs
acted as partial agonists and differentially affected
lymphocytes poised at distinct activation thresholds.
Moreover, one variant, H9-RETR, antagonized IL-2
and IL-15 better than blocking antibodies against
IL-2Ra or IL-2Rb. Furthermore, this mutein pro-
longed survival in a model of graft-versus-host
disease and blocked spontaneous proliferation of
smoldering adult T cell leukemia (ATL) T cells. This
receptor-clamping approach might be a general
mechanism-based strategy for engineering cytokine
partial agonists for therapeutic immunomodulation.
INTRODUCTION
Interleukin-2 (IL-2) is a four a-helical bundle type I cytokine (Boy-
man and Sprent, 2012; Cheng et al., 2011; Liao et al., 2013; Roch-
man et al., 2009) that signals through heterodimerization of the
IL-2Rb and the IL-2Rg (now known as the common cytokine re-
ceptor g chain, gc) receptor subunits (Nakamura et al., 1994;
Nelson et al., 1994). Discovered as T cell growth factor (Morgan
et al., 1976), IL-2 is a pleiotropic cytokine that also modulates
the differentiation of T helper cells (Laurence et al., 2007; Liao826 Immunity 42, 826–838, May 19, 2015 ª2015 Elsevier Inc.et al., 2008, 2011; Zhu et al., 2010), promotes regulatory T (Treg)
cell development (Cheng et al., 2011; Yu et al., 2009), augments
cytolytic activity of natural killer and lymphokine-activated killer
cells (Liao et al., 2013), mediates activation-induced cell death
(AICD) (Lenardo, 1991), and regulates effector versus memory
CD8+ T cell generation (Kalia et al., 2010; Pipkin et al., 2010).
On resting lymphocytes, IL-2 signals via intermediate-affinity
receptors (Kd 109 M) consisting of IL-2Rb and gc, whereas
activated lymphocytes and Treg cells additionally express IL-
2Ra, which combines with IL-2Rb and gc to form high-affinity
receptors (Kd 1011 M) (Cheng et al., 2011; Liao et al., 2013).
Whereas gc is shared by the receptors for IL-4, IL-7, IL-9, IL-15,
and IL-21 (Rochman et al., 2009) and is encoded by the gene
mutated in humans with X-linked severe combined immunodefi-
ciency (Noguchi et al., 1993), IL-2Rb is shared by the receptor for
IL-15 (Waldmann, 2006), a cytokine critical for normal develop-
ment of NK cells and memory CD8+ T cells (Waldmann, 2006).
Analogous to IL-2Ra, IL-15 also has a sushi-domain-containing
third subunit, IL-15Ra (Rochman et al., 2009; Waldmann, 2006).
IL-2 signals via three principal signaling pathways, the JAK-
STAT pathway (mainly activating JAK1, JAK3, STAT5A, and
STAT5B), the RAS-MAP kinase pathways, and the PI 3-kinase-
AKT pathway (Kim et al., 2006), which together contribute to
the rangeof biological actionsmediatedby IL-2 (Liao et al., 2013).
IL-2 can induce the expansion of T cells to enhance adoptive
immunotherapy and is approved by the FDA for the treatment
of melanoma and renal cell carcinoma, with complete remission
in a subset of patients (Rosenberg, 2014). However, IL-2 can
also promote pathologic responses, and a therapeutic goal is
to maintain the desired actions of this cytokine while blocking
untoward deleterious responses. Blocking IL-2 can also be
efficacious, and two monoclonal antibodies (mAbs) to human
IL-2Ra, Daclizumab and Basiliximab, are approved by the FDA,
with utility in preventing, for example, renal (Vincenti et al.,
1998) and cardiac (Beniaminovitz et al., 2000; Hershberger
et al., 2005) transplantation rejection and in treatingmultiple scle-
rosis (Bielekova et al., 2004; Gold et al., 2013). However, these
antibodies cannot block IL-2 signaling via intermediate-affinity
IL-2Rb-gc receptors expressed on NK and memory CD8
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Figure 1. Generation of Mechanism-Based
IL-2 Variants by Disrupting gc Binding.
(A) Left: The green region indicates the changes in
IL-2 used to generate H9 ‘‘super-IL-2’’ with high-
affinity binding to IL-2Rb (Levin et al., 2012),
thus blocking the binding of endogenous IL-2
(indicated by the red ‘‘X’’). The red circle indicates
changes in H9 that decrease binding to gc and
thus IL-2Rb-gc heterodimerization. Right: De-
pending on the degree of disruption of gc binding,
different activity potency and function should be
generated, as indicated.
(B) Structure of the H9-IL-2Rb-gc complex (H9 is
green; IL-2Rb is blue; gc is gold). The mutations
(L18R, Q22E, Q126T, and S130R) incorporated
into H9-RETR to disrupt the interaction of IL-2 with
gc are shown in cyan (right).
(C and D) Surface plasmon resonance analysis of
the binding of H9-IL-2Rb (C) and H9-RET-IL-2Rb
(D) complexes to gc.T cells. Although anti-human IL-2RbmAbMikb1 can block trans-
presentation of IL-2 and IL-15 to cells expressing IL-2Rb-gc re-
ceptors (Morris et al., 2006), it is relatively ineffective in blocking
cis-signaling by IL-2 or IL-15 via their high-affinity heterotrimeric
receptors (Morris et al., 2006; Waldmann et al., 2013).
We have previously used the structure of the high-affinity
IL-2-IL-2R complex (Rickert et al., 2005; Wang et al., 2005) to
develop IL-2 ‘‘superkines’’ with augmented action due to
enhanced binding affinity for IL-2Rb, which eliminates the func-
tional requirement for IL-2Ra (Levin et al., 2012). We now have
used this super-IL-2 platform to generate mutants that retain
increased binding affinity for IL-2Rb but that exhibited
decreased binding to gc and thereby defective IL-2Rb-gc heter-
odimerization and signaling. These are mechanism-based IL-2
partial agonists that can act as IL-2-receptor-signaling
‘‘clamps’’ and allow fine tuning of the signaling amplitude.
We have characterized the signaling effects and patterns of
gene induction induced by these IL-2 variants as well as their
functional effects. One of these partial agonists, H9-RETR,
was a potent antagonist of both IL-2 and IL-15 signaling andImmunity 42, 826–8function in vitro, inhibiting T cell prolifer-
ation and NK cytolytic activity. More-
over, it inhibited spontaneous prolifera-
tion of smoldering adult T cell leukemia
(ATL) T cells ex vivo and was superior
to blocking antibodies against IL-2Ra
and IL-2Rb. Furthermore, a stabilized
Fc-fusion version of H9-RETR prolonged
survival in a murine model of graft-
versus-host disease after allogeneic
bone-marrow transplantation.
RESULTS
Partial IL-2 Agonists Can Be
Engineered as IL-2 Receptor
Signaling ‘‘Clamps’’
In order to elucidate the signaling and bio-
logical actions of IL-2 as well as to createmolecules with therapeutic potential, we sought to create next-
generation analogs of IL-2 with diminished or absent signaling
amplitudes. We hypothesized that it would be possible to
‘‘clamp’’ IL-2 signaling strength in a manner that is relatively
insensitive to ligand concentration and that this might controlla-
bly offer the ability to modulate IL-2 signaling to varying degrees.
We speculated that IL-2 ‘‘superkines’’ with augmented action
due to enhanced binding affinity for IL-2Rb (Levin et al., 2012)
could serve as a dominant-negative scaffold to create a ‘‘recep-
tor signaling clamp’’ to block endogenous signaling. Directed
mutation to diminish binding to gc would then attenuate IL-
2Rb-gc heterodimerization and represent a class of mecha-
nism-based IL-2 partial agonists and non-signaling (neutral)
molecules that act as antagonists (see schematic in Figure 1A).
Based on the human IL-2-IL-2R crystal structure (Wang et al.,
2005) and structure-function studies with mouse IL-2 (Zurawski
et al., 1993), we identified four key residues at the human
IL-2-gc interface (Figure 1B) and generated H9 variants contain-
ing one (Q126T), two (L18R, Q22E), three (L18R, Q22E, and
Q126T), or four (L18R, Q22E, Q126T, and S130R) mutations38, May 19, 2015 ª2015 Elsevier Inc. 827
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Figure 2. Attenuated Signaling by IL-2 Variants
(A and B) Wild-type IL-2 or the indicated H9 variants were assayed for their ability to induce STAT5 phosphorylation in CD25 (A) and CD25+ (B) YT-1 human
NK-like cells. The EC50 values are indicated below the panels.
(C and D) Internalization kinetics of IL-2Rb (C) and gc (D) relative to maximal surface expression in CD25
 YT-1 cells after stimulation with the indicated IL-2
variants.
(E) Freshly isolated human CD8+ T cells (top) or CD8+ T cells pre-activated with anti-CD3 + anti-CD28 (bottom) were left unstimulated or stimulated with 1 mg/ml
IL-2, H9, H9-RE, H9-T, H9-RET, or H9-RETR for 30 min. CD25 expression (left) or pSTAT5 (right) were assayed by flow cytometry.
(legend continued on next page)
828 Immunity 42, 826–838, May 19, 2015 ª2015 Elsevier Inc.
AIL-2 H9 H9-RET H9-RETR Control
0
6
12
18
0
2
4
6
24
Fresh CD8+
T cells
Pre-activated
  CD8+ T cells
3 H
-th
ym
id
in
e 
in
co
rp
or
at
io
n 
(C
PM
 x1
0-3
) 500 50 
5 
0.5 
Cytokine (ng/ml)
IL-2
H9-RE
H9-T
H9-RET
H9-RETR
H9
CFSE
101 102 103 104 105
100
200
300
400
500
0
Ev
en
ts
No stimulation
B
CD25
Ev
en
ts
105104103102101
951
11598
11368
8501
5000
325
400
MFI:
IL-2
H9-RE
H9-T
H9-RET
H9-RETR
H9
200
400
600
0
No stimulation
C
Figure 3. Graded IL-2 Signaling Strength
Exerted by the IL-2 Analogs Can Differen-
tially Affect Lymphocyte Proliferation and
Cellular Activation
(A) Proliferation in response to IL-2, H9, H9-RE,
H9-T, H9-RET, and H9-RETR. Induction of prolif-
eration of freshly isolated human CD8+ T cells by
IL-2 and H9 but not by H9-RET or H9-RETR, with
intermediate effects of H9-T. Cells were labeled
with CFSE and stimulated with the indicated IL-2
variants, and CFSE dilution was assessed by flow
cytometry 5 days later.
(B) Freshly isolated human CD8+ T cells and CD8+
T cells pre-activated with anti-CD3 + anti-CD28
were cultured in 96-well plates with varying con-
centrations of the indicated IL-2 variants for 2 days
and [3H]thymidine incorporation measured. Bars
represent mean ± SEM. Cells were combined from
two donors. Data are representative of two inde-
pendent experiments performed in triplicate.
(C) CD25 expression on CD8+ T cells pre-activated
with anti-CD3 + anti-CD28 and then treated with
IL-2, H9, H9-RE, H9-T, H9-RET, or H9-RETR. Data
are representative of three independent experi-
ments. MFIs are indicated.(denoted as H9-T, H9-RE, H9-RET, and H9-RETR, respectively,
based on the newly introduced amino acids). By surface plasmon
resonance, recombinant H9 and H9-RET proteins had similar af-
finities for IL-2Rb, but whereas the H9-IL-2Rb complex efficiently
bound gc (Figure 1C), H9-RET-IL-2Rb did not (Figure 1D).
IL-2 Signaling Strength Inversely Correlates with the
Degree of Mutation at the gc Interface
To determine the activity of the H9 variants, we purified CD25+
and CD25 subpopulations of NK-like YT-1 cells and quantified
signaling. The H9 mutants behaved as IL-2 partial agonists, pro-
ducing a range of signaling efficacies from >90% down to <10%
of the wild-type Emax (maximum possible effect) of phosphoryla-
tion of STAT5 (Figures 2A and 2B), with the activity for each(F) Cells were treated with IL-2, H9, H9-RET, or H9-RETR, lysed, and immunoblotted with antibodies to pST
(G) Dose-response curves of pSTAT5 induced by IL-2, H9-RE, H9-T, H9-RET, and H9-RETR.
(H) Dose-response curves of phospho-S6 ribosomal protein (pS6) by IL-2, H9, H9-RET, and H9-RETR.
For dose-response experiments (A, B, G, H), the abscissa indicates the log of cytokine concentration in
representative of at least two experiments per panel (error bars, SEM of triplicates). See also Figure S1.
Immunity 42, 826–8analog inversely correlating with the de-
gree of mutation at the gc interface.
Signaling potency was relatively indepen-
dent of IL-2Ra, as demonstrated by the
relative Emax values for the H9 variants
on CD25 (Figure 2A) versus CD25+ (Fig-
ure 2B) YT-1 cells, suggesting that altered
binding to gc was primarily responsible
for the behavior of the H9 variants. H9-
RET and H9-RETR also exhibited dimin-
ished induction of other IL-2 signaling
pathways, including pERK1-pERK2 in
CD25 and CD25+ YT-1 cells (Figures
S1A and S1B). Moreover, IL-2 induces
internalization of IL-2Rb and gc (He´maret al., 1995), but whereas both H9-RET and H9-RETR drove
rapid and complete IL-2Rb internalization analogous to IL-2
and H9 (Figure 2C), they were much less efficient in driving inter-
nalization of gc (Figure 2D), consistent with their diminished bind-
ing to gc. Thus, variably disrupting the gc-binding interface of H9
can yield a variety of IL-2 partial agonists, potentially with a range
of signaling efficacies.
We next analyzed these molecules by utilizing primary cells,
and neither H9-RET norH9-RETRcould inducepSTAT5 in freshly
isolated human CD8+ T cells (Figures 2E and 2F, top), which ex-
press less IL-2Rb and gc than activatedCD8
+ T cells (Figure S1C,
upper versus lower) and little or no IL-2Ra (Figure 2E, left top).
However, after activation of CD8+ T cells with anti-CD3 + anti-
CD28, although H9-RETR remained essentially inert, H9-RETAT5 or total STAT5.
ng/ml. MFI, mean fluorescent intensity. Data are
38, May 19, 2015 ª2015 Elsevier Inc. 829
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Figure 4. Comparison of Global STAT5 Binding and Gene Expression Profiles of IL-2 versus IL-2 Analogs
(A) RNA-seq heatmap analysis of humanCD8+ T cells pre-activatedwith anti-CD3 + anti-CD28 and then treatedwith IL-2, H9, H9-RET, and H9-RETR (1 mg/ml) for
24 hr. Shown are the genes whose expression in the treated samples were at least twice (red) or less than half (green) that found in the control (expression of each
gene was normalized between 1.00 and 1.00 according to the color scale).
(B) Number of mRNAs upregulated (open bars) or downregulated (solid bars) after stimulation with indicated cytokines. IL-2, H9, H9-RET, and H9-RETR,
respectively, induced 731, 742, 65, and 23 mRNAs and repressed 437, 397, 13, and 46 mRNAs (fold changeR 2; p value < 1 3 1010).
(C) Number of STAT5B binding sites in CD8+ T cells pre-activated with anti-CD3 + anti-CD28 and then treated with the IL-2 variants based on ChIP-seq data and
their genome-wide distribution. Shown are 50 untranslated regions (50 UTR), exons, introns, and 30 untranslated regions (30 UTR) as defined in human RefSeq
database assembly GRCh37.p9. 5 kb upstream of TSS was designated as the promoter region.
(legend continued on next page)
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induced partial phosphorylation of STAT5 (Figure 2E, bottom
right; Figure 2F, bottom; Figure 2G) and S6 ribosomal protein
(Figure 2H). H9-T induced low pSTAT5 in freshly isolated CD8+
T cells (Figure 2E, top right), and this was markedly increased in
CD8+ T cells pre-activated with anti-CD3 + anti-CD28, albeit still
not up to the amount of pSTAT5 observedwith IL-2, H9, or H9-RE
(Figure 2E, bottom right and Figure 2G). Thus, H9-T and H9-RET
exhibit intermediate activities typical of partial agonists.
Differential Effects on Proliferation Depending on the
Activation State of the Cells
Given the weak pSTAT5 expression induced by H9-RET and
H9-RETR, we next investigated their effects on proliferation.
Whereas IL-2, H9, and H9-RE strongly induced proliferation of
primary human CD8+ T cells and H9-T was intermediate in its
effects, neither H9-RET nor H9-RETR induced proliferation of
these cells as assessed by carboxyfluorescein diacetate succini-
midyl diester (CFSE) dilution (Figure 3A) or by [3H]thymidine
incorporation (Figure 3B, top). However, when CD8+ T cells
were pre-activated with anti-CD3 + anti-CD28, H9-RETR still
had no effect, but H9-RET reproducibly induced proliferation
(Figure 3B, bottom). Thus, H9-RET induces different functional
outcomes in distinct cell subsets, analogous to its differential ef-
fects on pSTAT5 in freshly isolated CD8+ T cells versus CD8+
T cells pre-activated with anti-CD3 + anti-CD28 (Figure 2E). As
expected, IL-2 and H9 potently induced IL-2Ra expression in
CD8+ T cells pre-activated with anti-CD3 + anti-CD28, H9-RE
and H9-T were intermediate in their IL-2Ra induction, but
H9-RET and H9-RETR decreased IL-2Ra expression, actually
to below the control (Figure 3C), presumably reflecting their
competing with endogenous IL-2.
Attenuation of Gene Expression by H9-RET and
H9-RETR Correlates with Defective STAT5 Activation
We next used RNA-seq to further elucidate the basis for the
actions of IL-2 and H9 versus H9-RET and H9-RETR in human
CD8+ T cells pre-activated with anti-CD3 + anti-CD28 (Figures
4A and 4B). As expected, IL-2 and H9 induced genes that control
cell cycle or are involved in cytokine signaling (e.g., IL2RA,
CCND2, CISH, and CDK6) but repressed many other genes
(e.g., IL7R, BCL6), whereas H9-RET had only weak stimulatory
activity and H9-RETR had almost no effect (Figure 4A and Table
S1), revealing quantitative and qualitative differences in gene
expression induced by full and partial agonists. IL-2 and H9
induced more genes than they repressed, whereas H9-RETR
repressed more genes than it induced, although its overall effect
was minimal (Figure 4B). Because STAT5 is a key mediator of IL-
2-induced transcription, we used chromatin immunoprecipita-
tion coupled to next generation sequencing (ChIP-seq) to glob-
ally evaluate genomic STAT5 binding. H9-RET and H9-RETR
induced STAT5 binding to consensus 50-TTCnnnGAA-30 motifs,
but at far fewer sites than observed with either IL-2 or H9 (Fig-(D) IL-2-induced STAT5B peaks at 1 hr of stimulation were used to perform heat
‘‘peak summit’’ (indicated by position ‘‘0’’). The strength of binding induced by IL-2
the number of IL-2-induced STAT5B binding sites.
(E) Expression of IL2RA, LTA, CISH, IL7R, and BCL6 RNA relative to RPL7 in hum
stimulated with IL-2, H9, H9-RET, and H9-RETR for 24 hr. Data are representative
genes were confirmed by RT-PCR. Shown is mean ± SEM.ure 4C). Based on heat map clustering, only 35% of IL-2-
induced STAT5 sites were also induced by H9-RET, whereas
H9-RETR had little effect (Figure 4D). The induction (IL2RA,
LTA, CISH) or repression (IL7R, BCL6) of several STAT5 target
genes by IL-2 and H9 in CD8+ T cells pre-activated with anti-
CD3 + anti-CD28 was confirmed by RT-PCR (Figure 4E),
whereas neither H9-RET nor H9-RETR had an effect, except
that interestingly, unlike RETR, RET reproducibly lowered
BCL6 expression (Figure 4E), indicating that the H9-RET partial
agonist induces a sufficient signal to mediate partial repression
of this gene, whereas H9-RETR did not, again indicating distinc-
tive behavior by these molecules.
H9-RETR Potently Blocks Cytokine Signaling and NK
Cell Activity with Efficacy Similar or Greater than that of
Blocking Antibodies to IL-2Ra and IL-2Rb
The above studies established the attenuated activity of H9-
RET and negligible activity of H9-RETR, which effectively is a
dominant-negative antagonist of IL-2. Given their enhanced
binding to IL-2Rb and ability to decrease IL-2Ra expression
on CD8+ T cells pre-activated with anti-CD3 + anti-CD28, we
hypothesized that these molecules would inhibit not only
endogenous IL-2, but also IL-15, which also signals via IL-
2Rb and gc. Indeed, both H9-RET and H9-RETR inhibited IL-
2-induced (Figure 5A) and IL-15-induced (Figure 5B) pSTAT5
in CD8+ T cells, with H9-RETR being more potent. This inhibi-
tion correlated with the ability of H9-RET and H9-RETR to
lower T cell receptor (TCR)-induced (Figure 3C) and IL-2-
induced (Figure S2A) CD25 expression to below the expression
observed in unstimulated control cells. Correspondingly, in
human CD8+ T cells pre-activated with anti-CD3 + anti-CD28,
H9-RET and H9-RETR inhibited IL-2-induced proliferation (Fig-
ure S2B, left), with corresponding effects on IL-15-induced
proliferation as well (Figure S2B, right). We speculated that
H9-RET and H9-RETR would also inhibit TCR-induced prolifer-
ation, which depends on IL-2, and this was indeed the case
(Figure S2C) and correlated with decreased CD25 expression
(Figure S2D). Similarly, in contrast to IL-2, which promotes
Th1, Th9, and Treg cell differentiation but inhibits Th17
cell differentiation (Liao et al., 2013), H9-RET and H9-RETR
inhibited Th1, Th9, and Treg cell differentiation but augmented
Th17 cell differentiation (Figure S2E), underscoring their ability
to potently antagonize IL-2. The activation of primary human
NK cells by IL-2 was also potently blocked by H9-RETR,
as measured by IL-2-induced CD69 expression (Figure 5C),
and cytotoxicity toward the breast cancer cell line HER18 (Fig-
ure 5D) and the chronic myelogenous leukemia cell line K562
(Figure 5E) were also inhibited by H9-RETR. Neither H9-RET
nor H9-RETR stimulated CD69 expression (Figure 5C) or cyto-
toxicity by primary NK cells (Figure 5D).
Given H9-RETR’s effectiveness as an IL-2 and IL-15 antag-
onist in vitro, we wished to investigate its ability to antagonizemap clustering centered 1 kb upstream and 1 kb downstream of the STAT
, H9, H9-RET, and H9-RETR is indicated by the intensity of red. 10322 (y axis) is
an CD8+ T cells pre-activated with anti-CD3 + anti-CD28 left unstimulated or
of at least two experiments, except for the RNA-seq experiment, in which select
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Figure 6. In Vivo Efficacy of the Mechanism-Based IL-2 Antagonist, H9-RETR
(A) H9-RETR inhibits IL-2-induced (middle) and IL-15-induced (right) STAT5 phosphorylation in vivo. C57BL/6 mice were injected (i.p.) with Fc4 (100 mg) or
H9-RETR-Fc4 (100 mg) 60 min prior to IL-2 or IL-15 (2 mg). Schematic of the protocol for the experiment is shown. pSTAT5 was measured 30 min later in splenic
CD4+CD25+FoxP3+ T cells. MFIs are indicated. Data are representative of three independent experiments.
(B) H9-RETR-Fc4 attenuates GVHD. BALB/c mice were irradiated (950 cGy) and transplanted with 10 million T-cell-depleted bone marrow (BM) cells without or
with 2million Treg-cell-depleted pan-T cells fromC57BL/6mice.Mice receiving pan-T cells were treatedwith Fc4 or H9-RETR-Fc4 fusion protein by i.p. injections
for 10 days with 100 mg/dose twice a day. Data represent survival curves pooled from three independent experiments and analyzed using the Kaplan-Meier
method and the log-rank test. p = 0.0001 for Fc4 versus H9-RETR-Fc4.
See also Figure S3.endogenous cytokines in vivo. Because IL-2 has a short
serum half-life (Donohue and Rosenberg, 1983), we fused
H9-RETR to the Fc fragment of human IgG4 (Fc4), an isotype
with diminished antibody-dependent cellular cytotoxicity
(ADCC) and antibody-dependent cellular phagocytosis
(ADCP) (Strohl, 2009). When tested in vitro, as compared to
anti-Tac mAb to CD25 and Mikb1 mAb to IL-2Rb (Morris
et al., 2006), H9-RETR-Fc4 more potently blocked IL-2-medi-Figure 5. H9-RETR Potently Inhibits IL-2R-Mediated Signaling
(A and B) H9-RET and H9-RETR are competitive inhibitors of IL-2 (A) and IL-15 (B)
with the indicated concentrations of IL-2 or IL-15 in the absence or presence of
(C–E) H9-RETR blocks IL-2-induced NK cell activation and cytotoxicity.
(C) Unlike IL-2, neither H9-RET nor H9-RETR (1 mg/ml) stimulated CD69 expressi
IL-2 (100 ng/ml)-induced CD69 expression. The experiment was performed twic
(D and E) Neither H9-RET nor H9-RETR stimulated cytotoxicity in primary humanN
HER18 (D) and K562 (E) target cells. NK cells and target cells were incubated at a 1
determined by 51Cr release and performed in triplicate; lysis of K562 cells was a
(F and G) H9-RETR more potently blocks IL-2-induced (F) and IL-15-induced (G
pre-activated with anti-CD3 + anti-CD28.
(H and I) H9-RETR more potently inhibits IL-2-induced (H) or IL-15-induced (I) pr
Shown are means ± SEM. Data are representative of three independent experimated (Figure 5F) and IL-15-mediated (Figure 5G) pSTAT5
induction in CD8+ T cells pre-activated with anti-CD3 +
anti-CD28 and inhibited IL-2-induced (Figure 5H) and IL-15-
induced (Figure 5I) proliferation of human CD8+ T cells. More-
over, H9-RETR-Fc4 was as effective as the combination of
anti-Tac and Mikb1 in blocking IL-2 proliferation (Figure 5H)
and more potent than Mikb1 in inhibiting IL-15-induced prolif-
eration (Figure 5I).. Human CD8+ T cells pre-activated with anti-CD3 + anti-CD28 were incubated
1 mg/ml of H9-RET or H9-RETR.
on in primary human NK cells after incubation for 24 hr, but H9-RETR inhibited
e.
K cells, andH9-RETR at 103 ng/ml inhibited IL-2-inducedNK cell cytotoxicity of
0:1 ratio for 4 hr in the presence of the indicated cytokines. HER18 cell lysis was
ssessed by flow cytometry. Four independent experiments were performed.
) STAT5 phosphorylation than anti-Tac or Mikb1 mAbs in human CD8+ T cells
oliferation than anti-Tac or Mikb1.
ents. See also Figure S2.
Immunity 42, 826–838, May 19, 2015 ª2015 Elsevier Inc. 833
020
40
60
80
100 ***
***
***
ED40515(+)
cells
C
3 H
 u
pt
ak
e 
(cp
m 
x 1
0-3
)
0
10
20
30
40
50
*
***
***
Smoldering ATL
D
3 H
 u
pt
ak
e 
(cp
m 
x 1
0-3
)
IL-2    -      +  +  +  +  +  +
2000
2000
3000
4000
5000
0
+ inhibitor (log [nM)
420-2IL-2 6
pS
TA
T5
 (M
FI)
IL-2 (1 ng/ml)
+ Daclizumab
+ H9-RETR-Fc4
+ log [inhibitor (nM)]
420-2IL-2 6
12000
10000
8000
6000
4000
2000
0
IL-2 (10 ng/ml)
+ Daclizumab
+ H9-RETR-Fc4
A B
H9-RETR-Fc4 Daclizumab
IC50(nM)
0.013
(0.0049 -0.036)
361.7
(147.8-885.9)
pS
TA
T5
 (M
FI)
Figure 7. H9-RETR Potently Inhibits IL-2-
Induced pSTAT5 Signaling and the Prolifer-
ation of Smoldering ATL Cells
(A and B) Dose-response effect of increasing
concentration of H9-RETR-Fc4-fusion protein
versus daclizumab on IL-2-induced pSTAT5 in
human CD8+ T cells pre-activated with anti-CD3 +
anti-CD28. CD8+ T cells were pre-activated
with anti-CD3 and anti-CD28 and cultured as
described in the Experimental Procedures and
incubated with the indicated concentration of H9-
RETR-Fc4 or daclizumab for 30 min, re-stimulated
with 1 ng/ml (A) or 10 ng/ml (B) IL-2 for 20 min, and
pSTAT5 was measured by flow cytometry. Data
are representative of two independent experi-
ments. The IC50 values for H9-RETR-Fc4 and
daclizumab are indicated below (A).
(C) Blocking of proliferation of ED40515(+) T cells
cultured with 50 U/ml IL-2 for 3 days in the
presence or absence of UPC10 (a murine IgG2a
monoclonal antibody that does not recognize
resting or activated human blood lymphocytes),
daclizumab, Mikb1, or H9-RETR, as indicated.
Data are representative of two experiments, each
performed in triplicate.
(D) Spontaneous 6 day proliferation assay of
cells from a patient with smoldering ATL, treated
with UPC10, daclizumab, Mikb1, or H9-RETR.
Assays were performed in triplicate. *p < 0.05;
***p < 0.001.
Shown are means ± SEM.Potent Inhibitory Actions of H9-RETR In Vivo
We next evaluated H9-RETR-Fc4 in vivo. Under steady-state
conditions, Treg cells are the dominant population of primary
cells expressing high-affinity IL-2 receptors (Boyman and
Sprent, 2012; Cheng et al., 2011; Liao et al., 2013; Littman and
Rudensky, 2010) and can act as a systemic ‘‘barometer’’ of
IL-2 signaling. Pre-treating mice with H9-RETR-Fc4 for 60 min
prior to administering IL-2 or IL-15 inhibited phosphorylation of
STAT5 in CD4+FoxP3+ Treg cells, as assessed ex vivo (Fig-
ure 6A). Next, we tested the relative efficacy of H9-RETR-Fc4
versus anti-IL-2Ra mAb (clone PC61) in blocking IL-2 signaling
in vivo (Figure S3) and found that H9-RETR-Fc4 was more
effective in blocking IL-2-induced pSTAT5 signaling in Treg cells.
These data demonstrated in vivo potential of H9-RETR-Fc4 as a
potent IL-2 antagonist. Because IL-2 and IL-15 signaling contrib-
utes to acute graft-versus-host disease (GVHD) in experimental
murine models (Blaser et al., 2005; Chinen and Buckley, 2010;
Ferrara et al., 1986), we hypothesized that H9-RETR-Fc4
might inhibit lethal GVHD in a T-cell-mediated C57BL/6-into-
BALB/C model of fully-MHC mismatched bone marrow trans-
plantation. Indeed, mice treated for 10 days with H9-RETR-Fc4
had longer survival than mice receiving control Fc4 protein
(Figure 6B).
H9-RETR Potently Blocks IL-2 Signaling and Inhibits the
Spontaneous Proliferation of Smoldering Adult T Cell
Leukemia Cells
We next compared the inhibitory potency of H9-RETR-Fc4 with
daclizumab and found that H9-RETR-Fc4 was more potent in
blocking IL-2-induced phosphorylation of STAT5 in CD8+834 Immunity 42, 826–838, May 19, 2015 ª2015 Elsevier Inc.T cells pre-activated with anti-CD3 + anti-CD28 (Figures 7A
and 7B). However, daclizumab had little effect on signaling in
response to high-dose IL-2 (10 ng/ml), a dose capable of titrating
intermediate-affinity receptors (Figure 7B). These results under-
score the inhibitory potency of H9-RETR-Fc4.
Human T cell lymphotropic virus-I (HTLV-I) causes adult T cell
leukemia (ATL), a malignant expansion of CD4+ T cells that ex-
hibits an early growth phase that involves autocrine signals by
IL-2 and IL-15 and paracrine signals by IL-9. Such cytokine-
dependent proliferation occurs in patientswith chronic and smol-
dering but not acute ATL (Ju et al., 2011). To test the efficacy of
H9-RETR in ATL, we first used ATL-derived ED40515 cells, and
H9-RETR potently inhibited IL-2-induced proliferation of these
cells and was superior to either daclizumab or Mikb1 (Figure 7C).
Moreover, H9-RETR at 10 mg/ml was at least as effective as
daclizumab and much more effective than Mikb1 in inhibiting
spontaneous proliferation of cells freshly isolated from a patient
with smoldering ATL (Figure 7D), underscoring its potential utility
in the control of these vigorously proliferating malignant cells.
DISCUSSION
Partial agonism, defined as reduced signaling amplitude (Emax)
at ligand saturation, is a pharmacological property typically
associated with small molecules targeting G protein-coupled
receptors (Strange, 2008), but to a lesser degree for type I trans-
membrane receptors that signal as dimers (Levin et al., 2014;
Riese, 2011). A technical limitation to achieving partial agonism
of a dimeric receptor is that, in most cases, wild-type dimerizing
ligands (e.g., cytokines, growth factors, etc.) have relatively low
affinity for individual receptor subunits as compared to the dimer
and are therefore inefficient clamps. Thus, a dimerizing ligand
engineered for high affinity to one of the receptor subunits
enables the cytokine to efficiently act as a dominant-negative
signal modulator, as has been seen in the interferon system
(Levin et al., 2014). Here, we engineered IL-2 variants by
enhancing affinity at one receptor binding site (IL-2Rb) while
attenuating interactions at the second receptor binding site (gc)
in order to manipulate dimerization and signal initiation. Because
of augmented binding to IL-2Rb, thesemolecules were dominant
over endogenous IL-2, and their degree of interaction with gc set
the intensity of the signal appreciated by the cell, thereby
‘‘clamping’’ signaling amplitude at the partial agonist’s Emax.
Using these partial agonists, we demonstrated that freshly
isolated CD8+ T cells and CD8+ T cells pre-activated with anti-
CD3 + anti-CD28 had distinct activation thresholds for IL-2
signaling strength, as evidenced by differential effects of H9-T
and H9-RET on these cells, whereas H9-RETR, which is an
extremely weak partial agonist as shown by its low pSTAT5
induction, had marked inhibitory properties, with potential as
an immunosuppressive agent. In particular, it blocked IL-2Ra
induction, prolonged survival in a GVHD model, and potently in-
hibited the spontaneous proliferation of peripheral blood T cells
from a patient with smoldering ATL. Moreover, H9-RETR in-
hibited NK-mediated cytotoxicity.
The effectiveness of anti-CD25 (anti-IL-2Ra) monoclonal anti-
bodies that disrupt high-affinity IL-2 receptor-mediated signaling
has stimulated considerable interest in the potential to regulate
IL-2 activity as a means of controlling autoimmune diseases
and organ rejection. H9-RETR, which is specific for IL-2Rb but
independent of IL-2Ra, might offer therapeutic utility, potentially
even in combination with anti-CD25-based therapy. Like H9-
RETR, H9-RET almost completely blocked Treg cell differentia-
tion, but unlike H9-RETR, H9-RET could induce proliferation of
CD8+ T cells pre-activatedwith anti-CD3 + anti-CD28.Moreover,
H9-T more potently activated STAT5 phosphorylation on acti-
vated T cells than on naive cells. These types of partial agonists,
unlike full agonists or complete antagonists, might offer the
ability to tune the signaling properties to an amplitude that
elicits desired functional properties while not meeting thresholds
for undesired properties. Given the differential activities of the
partial agonists, a larger repertoire of IL-2 variants could be
engineered to exhibit an even finer degree of distinctive sig-
naling activities, ranging from almost full to partial agonism to
complete antagonism. These could be valuable in dissecting
the pleiotropic functions of this cytokine on different immune
pathways and might have distinctive therapeutic benefits de-
pending on the context. Indeed, therapeutic agonism by IL-2
might not require the full agonist signal, and benefit might be
achievedbydelivering a reducedsignal amplitude that couldmiti-
gate toxicity. Moreover, the rational design approach we have
used can be adapted to other gc family cytokines and indeed
for a broader range of cytokines and growth factors as well.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Human IL-2 (amino acids 1–133) and variants thereof, the human IL-2Rb
ectodomain (amino acids 1–214), and the gc ectodomain (amino acids34–232), were secreted and purified via a baculovirus expression system,
as previously described (Wang et al., 2005). In brief, all construct sequences
were cloned into the pAcGP67A vector (BD Biosciences) with an N-terminal
gp67 signal peptide and a C-terminal hexahistidine tag. Spodoptera frugi-
perda (Sf9) insect cells cultured at 28C in SF900 II SFM medium (Invitrogen)
were transfected with the plasmid constructs to establish high-titer recombi-
nant virus, which was subsequently amplified. Trichopulsia ni (High-Five)
insect cells (Invitrogen) grown in Insect Xpress medium (Lonza) at 28C
were infected with the viruses to express recombinant protein (Kuziel
et al., 1993; Yodoi et al., 1985). Three days after infection, proteins were ex-
tracted via Ni-NTA (QIAGEN) affinity chromatography, concentrated, and
purified to >98% homogeneity with a Superdex 200 sizing column (GE
Healthcare) equilibrated in 10 mM HEPES (pH 7.3) and 150 mM NaCl. Fc4
and H9-RETR-Fc4 fusion proteins were also secreted and purified with this
system by cloning the human IgG4 Fc domain (Fc4) or the human IL-2
RETR variant followed by a C-terminal human IgG4 Fc domain (H9-RETR-
Fc4) into pAcGP67A vector containing an N-terminal gp67 signal peptide
and a C-terminal hexahistidine tag. Human IgG4 Fc domain was obtained
from a modified pFUSE-hIgG4-Fc vector (Invivogen) with an engineered
Ser228 Pro mutation (van der Neut Kolfschoten et al., 2007). For in vivo
experiments, endotoxin was removed with Triton X-114 as previously
described (Reichelt et al., 2006) and verified with the LAL Chromogenic
Endotoxin Quantitation Kit (Thermo Scientific).
For biotinylated protein expression, gc with a C-terminal biotin acceptor
peptide (BAP)-LNDIFEAQKIEWHE was expressed and purified via Ni-NTA
affinity chromatography and biotinylated with soluble BirA ligase enzyme in
0.5 mM Bicine (pH 8.3), 100 mM ATP, 100 mM magnesium acetate, and
500 mMbiotin (Sigma). Proteins were purified by size exclusion on a Superdex
200 column as above.Surface Plasmon Resonance Binding Measurements
Binding interactions were characterized via surface plasmon resonance
(SPR) with Biacore SA sensor chips (GE Healthcare) on a Biacore T100 in-
strument. gc was immobilized to the chip surface at low density (RUmax <
100 response units), and serial dilutions of H9:IL-2Rb or H9-RET:IL-2Rb
complexes were exposed to the surface for 60 s. Dissociation was then
tracked for 200 s. An irrelevant biotinylated protein was immobilized in
the reference channel to subtract non-specific binding. Experiments were
performed in HBS-P+ buffer (GE Healthcare) supplemented with 0.2%
BSA at 25C at a flow rate of 30 ml/min to minimize mass transport
contributions and prevent rebinding of the analyte. Data analysis and deter-
mination of equilibrium and kinetic parameters were implemented with the
Biacore T100 evaluation software v.2.0 assuming a 1:1 Langmuir binding
model.Tissue Culture and Magnetic Purification of CD25+ YT-1 Cells
Unmodified YT (Yodoi et al., 1985) and CD25+ YT-1 (Kuziel et al., 1993) natural
killer-like cells were cultured in RPMI complete medium (RPMI 1640 medium
with 10% fetal bovine serum, 2 mM L-glutamine, minimum non-essential
amino acids, sodium pyruvate, 25 mM HEPES, and penicillin-streptomycin
[GIBCO]) at 37C in a humidified atmosphere with 5% CO2.
Subpopulations of YT-1 cells expressing or not expressing CD25 were
purified via magnetic selection, as described (Ring et al., 2012). Ten million
unsorted CD25+ YT-1 cells were washed with flow cytometry buffer (phos-
phate-buffered saline [pH 7.2] containing 0.1% bovine serum albumin) and
incubated with PE-conjugated anti-human CD25 antibody (Biolegend, clone
BC96) in flow cytometry buffer for 2 hr at 4C. The PE-stained CD25+ cells
were labeled with paramagnetic microbeads conjugated to an anti-PE IgG
for 20 min at 4C, washed once with cold flow cytometry buffer, and sorted
with an LS MACS separation column (Miltenyi Biotec) according to the
manufacturer’s protocol. Eluted cells were re-suspended and grown in
RPMI complete medium and enrichment of CD25+ cells was evaluated
with an Accuri C6 flow cytometer. Persistence of CD25 expression on
the sorted CD25+ YT-1 cells was monitored by flow cytometric analysis
with PE-conjugated anti-human CD25 antibody. Detailed methods for
phosphor-flow analysis is described in the Supplemental Experimental
Procedures.Immunity 42, 826–838, May 19, 2015 ª2015 Elsevier Inc. 835
IL-2 Receptor Internalization Experiments
IL-2, H9, H9-RET, or H9 RETR (1 mM)was incubatedwith 33 105 YT-1 cells in a
96-well plate for 2, 5, 10, 15, 30, 60, 90, 120, 180, or 240min. Cells were imme-
diately transferred to ice to prevent further receptor internalization and washed
twice with ice-cold PBSA buffer (0.1% BSA in PBS) and stained with 1:50
dilutions of allophycocyanin-conjugated anti-human IL-2Rb antibody (TU27;
Biolegend) and phycoerythrin-conjugated anti-human IL-2Rg antibody
(TUGh4; Biolegend) in PBSA buffer for 30 min on ice. After two more washes
in ice-cold PBSA buffer, cells were fixed for 10 min at room temperature
with 1.5% paraformaldehyde in PBSA, washed, and resuspended in PBSA
buffer. Mean cell fluorescence was quantified with an Accuri C6 flow cyto-
meter. Internalization data were fitted to a single exponential decay model
via non-linear least-squares regression with the Prism software package
(GraphPad).
Human CD8+ T Cell Isolation and Intracellular Staining of pSTAT5
and pS6-Ribosomal Protein
Buffycoatswere fromhealthydonors from theNIHBloodBank.Peripheral blood
mononuclear cells (PBMCs) were isolated by gradient centrifugation using
lymphocyte separationmedium (Mediatech).Cellswere isolatedwith thehuman
CD8+ T cell isolation kit I (Miltenyi Biotec). To pre-activate cells, 6-well plates
were pre-coated with 2 mg/ml of plate-bound anti-CD3 mAb (BD Biosciences),
cells were seeded at 13 106 cells/ml in complete medium (RPMI medium sup-
plemented with glutamine, penicillin, streptomycin, and 10% FBS) with 1 mg/ml
soluble anti-CD28 mAb (BD Biosciences) for 3 days and then rested for 48 hr in
fresh medium. The methods for phospho-flow cytometry, thymidine incorpora-
tion, immunoblotting,CFSEdilution, andEdUproliferation assays are described
in the Supplemental Experimental Procedures.
Analysis of STAT5 Phosphorylation Ex Vivo
C57BL/6 mice were from the Jackson Laboratory. Animal protocols were
approved by the NHLBI Animal Care and Use Committee and followed the
NIH Guidelines, ‘‘Using Animals in Intramural Research.’’ STAT5 phosphoryla-
tion was assayed by the manufacturer’s protocol (BD Bioscience). In brief,
H9-RETR-Fc4 fusion protein or Fc4 control or anti-mouse IL-2Ra monoclonal
Ab PC61 (BioXcell) or rat IgG1 isotype control were injected i.p. into C57BL/6
mice 1 hr prior to IL-2 or IL-15 injection, and total splenocytes isolated, imme-
diately fixed with BD Phosphoflow Lyse/Fix buffer, washed twice with ice-cold
PBS, stained with anti-CD4 (Biolegend), and permeabilized with BD PhosFlow
Perm Buffer III for 30 min on ice in the dark. Cells were then washed twice with
ice-cold flow cytometry buffer, stained with anti-FoxP3 per the manufacturer’s
protocol (eBioscience), washed twice with ice-cold flow cytometry buffer, and
stained with anti-phospho-STAT5-PE (1:30) (BD) at room temperature for
30 min in the dark. Cells were washed three times with flow cytometry buffer
and data acquired on a BD FACSCanto II flow cytometer and analyzed with
FlowJo (Tree Star). We used human IL-2 for these mouse studies as is typical
(Rosenberg et al., 1985; Tang et al., 2008) given the proven efficacy of human
IL-2 in the mouse.
Proliferation of ED40515 Cells and Cells from a Patient with
Smoldering ATL
IL-2-dependent ED40515(+) (Maeda et al., 1985) cells were washed twice with
PBS. Cells were seeded into 96-well plates at 1 3 104 cells/well in 100 ml of
RPMI 1640 medium with or without IL-2 and with or without reagents and
then incubated at 37C for 3 days.
Blood samples from ATL patients were obtained under the care of the Clin-
ical Trials Team, Lymphoid Malignancies Branch, NCI, NIH. This study proto-
col was approved by the Institutional Review Board of the National Cancer
Institute. Informed consent was obtained in accordance with the Declaration
of Helsinki. Peripheral blood mononuclear cells (PBMCs) from ATL patients
were isolated by Ficoll-Hypaque density gradient centrifugation from heparin-
ized blood. Aliquots of 13 105 cells/100 ml/well were cultured ex vivo in RPMI
1640 medium supplemented with 10% FBS with or without reagents for
6 days. During the last 6 hr of culture, ED40515(+) cells or ATL PBMCs were
pulsed with 1 mCi (0.037 MBq) [3H]thymidine, and cells were then harvested
(Tomtec) and counted with a MicroBeta2 microplate counter (PerkEmer).
The assay was performed in triplicate.836 Immunity 42, 826–838, May 19, 2015 ª2015 Elsevier Inc.Activation of NK Cells and NK Cell Cytotoxicity Assay
Peripheral blood mononuclear cells (PBMCs) were cultured in the presence of
1 mg/ml IL-2 analogs for 24 hr. Cells were then stained with APC-conjugated
anti-CD56 (BD Biosciences), Pacific Blue-conjugated anti-CD3 (BioLegend),
and FITC-conjugated anti-CD69 (BD Biosciences). Samples were analyzed
by flow cytometry with a FACSAria II (BD Biosciences). NK cells were gated
as CD3-negative, CD56-positive.
PBMCs were isolated by gradient centrifugation with Ficoll-Paque Premium
(GE Life Sciences), and then untouched NK cells were purified with the Human
NK Cell Isolation Kit (Miltenyi) followed by separation with an autoMACS
(Miltenyi). HER18 target cells were labeled with 150 mCi 51Cr (Perkin Elmer)
per 1 3 106 cells for 2 hr. NK cells were added to 10,000 HER18 cells at a
10:1 effector:target ratio. Specific lysis was determined after 4 hr of culture
in the presence of varying concentrations of IL-2 variants.
Lysis of K562 cells by primary NK cells was performed as described
(Thomas et al., 2013). In brief, human NK cells were purified with a kit
(STEMCELL). K562 cells were labeled with the PKH67 green fluorescent cell
linker kit (Sigma-Aldrich) and NK cells were added to 5,000 K562 cells at a
10:1 ratio, cultured in the presence of varying concentrations of IL-2 variants
at 37C for 4 hr, and placed on ice to prevent further reactivity. Cells were
then stained with propidium iodide (PI) (Sigma-Aldrich) and the percentage
of PI+ PKH67+ K562 cells was determined by flow cytometry.
T Helper Cell Polarization and Intracellular Cytokine Staining
Naive CD4+ C57BL/6 T cells were differentiated under different T helper cell
polarization conditions in the absence or presence of the indicated cytokines.
Four days later, cells were first stained for surface antigens as indicated
and then with antibodies to IFN-g (eBioscience), IL-17A (eBioscience), IL-4
(BioLegend), IL-9 (BioLegend), or FoxP3 (eBioscience) in BD cytofix and
cytoperm or via the eBioscience FoxP3 staining buffer kit according to the
manufacturer’s protocol. Stained cells were analyzed on a FACSCanto II
flow cytometer (Becton Dickinson) with FlowJo software (Tree Star). All mouse
cytokines were from Peprotech.
RNA-Seq Analysis
CD8+ T cells were pre-activated with anti-CD3 + anti-CD28, rested for 2 days
in complete medium, and stimulated for 24 hr with 1 mg/ml of wild-type IL-2,
H9, H9-RET, or H9-RETR, and total RNA from 5 3 106 cells was isolated
(RNeasy kit, QIAGEN). RNA from five donors was pooled, and 1 mg of the
pooled RNA was used to synthesize cDNA. RNA-seq libraries were prepared
as described (Ring et al., 2012). PCR-amplified products were barcoded and
sequenced with an Illumina HiSeq2000 platform. Sequenced reads were
aligned against the human genome (hg18, NCBI build 36.1) with Bowtie
0.12.4 (Langmead et al., 2009). Uniquely mapped reads were retained, and
digital expression of genes was calculated with RPKM (Reads Per Kilobase
per Million mapped reads). R package edgeR was used to identify differ-
entially expressed genes, and fold-change (in log2 scale) differences
were compared between cells not treated or treated with the IL-2 variants
for 24 hr.
ChIP-Seq Library Preparation and Analysis
CD8+ T cells were pre-activated with anti-CD3 + anti-CD28, treated with
different cytokines for 90 min, and then chemically cross-linked with 1% para-
formaldehyde. Chromatin from 10–20 million cells was sonicated into 250–
500 bp fragments, immunoprecipitated with anti-STAT5B (Invitrogen), and
processed for sequencing as described (Liao et al., 2008). All reads were
aligned against the human genome (hg18, NCBI build 36.1) with Bowtie
0.12.4. Uniquely mapped reads were converted to browser extensible data
(BED) files and duplicated reads (multiple reads in same genomic location)
were filtered. The filtered (non-redundant) BED files were then converted to
binary tiled data (.tdf) and visualized with the Integrative Genome Viewer
(Broad Institute).
Gene Expression Analysis by RT-PCR
Total RNA was isolated with RNeasy Plus mini kit (QIAGEN) and 200 ng was
used together with oligo dT (Invitrogen) and the Omniscript reverse transcrip-
tion kit (Quiagen) to synthesize cDNA. Quantitative RT-PCR was performed
with an ABI 7900 HD Sequence Detection System. RT primers and probes
were from Applied Biosystems. Expression was normalized to RPL7.
Bone Marrow Transplantation into Allogeneic Hosts
7-week-old female C57BL/6 (H2K
b) and BALB/c (H2K
d) mice from the NCI-
Frederick Cancer Research Facility were maintained in a specific-pathogen-
free facility and treated according to an animal protocol approved by the
NCI Animal Care and Use Committee. BALB/c mice were conditioned with
950 cGy total body irradiation and then reconstituted with 10 million T-cell-
depleted bone marrow cells from C57BL/6 mice alone or together with 2
million Treg-cell-depleted pan-T cells. T cell depletion was performed with
anti-CD90 (Thy1.2) microbeads (total T cell depletion) or anti-CD25 (Treg cell
depletion) with kits fromMiltenyi Biotec. Mice receiving pan-T cells were addi-
tionally treated with Fc4 or H9-RETR-Fc4 (100 mg i.p. twice/day for 10 days).
Drinking water was supplemented with ciprofloxacin from day 1 to +14 after
total body irradiation. Survival was monitored. Survival was analyzed accord-
ing to the Kaplan-Meier method, and survival curves were compared via
the log-rank test. Statistical analysis was performed with GraphPad Prism 4
software.
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